The potential for targeting extracellular LOX proteins in human malignancy

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 1729-1735

  Mayorca Guiliani, Alejandro ^a   Erler, Janine T ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Extracellular matrix; Lysyl oxidase; Metastasis

Indexed keywords

COLLAGEN; ELASTIN; HYPOXIA INDUCIBLE FACTOR 1; LYSYL OXIDASE LIKE 1; LYSYL OXIDASE LIKE 2; LYSYL OXIDASE LIKE 3; LYSYL OXIDASE LIKE 5; PROTEIN LYSINE 6 OXIDASE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CANCER MORTALITY; CANCER STAGING; CANCER THERAPY; CELL INVASION; CELL PROLIFERATION; ENZYME INHIBITION; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PROTEIN CROSS LINKING; PROTEIN TARGETING; REVIEW;

EID: 84888591350     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S38110     Document Type: Review

References (47)

1. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196(4):395-406.
2. Gritsenko PG, Ilina O, Friedl P. Interstitial guidance of cancer invasion. J Pathol. 2012;226(2):185-199.
3. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nature Cancer Rev. 2012;12(8):540-552.
4. Agra N, Cidre F, García-García L, de la Parra J, Alonso J. Lysysl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displys tumor suppressor activities in ewing sarcoma cells. PLoS One. 2013;8(6):e66281.
5. Pinnell SR, Martin GR. The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide lynkage to alpha-aminoadipicdelta-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci U S A. 1968;61(2):708-716.
6. Hamalainen ER, Kemppainen R, Kuivaniemi H, et al. Quatitative polymerase chain reaction of lysil oxidase mRNA in malignantly transformed human cell liness demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem. 1995;270(37):21590-21593.
7. Contente S, Kenyon K, Rimoldi D, Friedman RM. Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science. 1990;249(4970):796-798.
8. Uzel MI, Scott IC, Babakhanlou-Chase H, et al. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem. 2001;276(25):22537-22543.
9. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4): 660-672.
10. Molnar J, Fong KS, He QP, et al. Structural and functional diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta. 2003;1647(1-2):220-224.
11. Mäki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol. 2009;24(5):651-660.
12. Cox TR, Bird D, Baker AM, et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 2013;73(6): 1721-1732.
13. Mäki JM, Sormunen R, Lippo S, Kaarteenaho-Wiik R, Soininen R, Myllyharju J. Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibres in various tissues. Am J Pathol. 2005;167(4):927-936.
14. Kuivaniemi H, Peltonen L, Kivirikko KI. Type IX Ehlers-Danlos syndrome and Menkes syndrome: the decrease in lysyl oxidase activity is associated with a corresponding deficiency in the enzyme protein. Am J Human Genet. 1985;37(4):798-808.
15. Yeowell HN, Walker LC. Mutations in the lysyl hydroxylase 1 gene that result in enzyme deficiency and the clinical phenotype of Ehlers-Danlos syndrome type VI. Mol Genet Metab. 2000;71(1-2):212-224.
16. Li PA, He Q, Cao T, et al. Up-regulation and altered distribution of lysyl oxidase in the centrak nervous system of mutant SOD1 transgenic mouse model of amyotrophic lateral sclerosis. Brain Res Mol Brain Res. 2004;120(2):115-122.
17. Gilad GM, Kagan HM, Gilad VH. Evidence for increased lysyl oxidase, the extracellular matrix-forming enzyme, in Alzheimer's disease brain. Neurosci Lett. 2005;376(3):210-214.
18. Liu X, Zhao Y, Gao J, et al. Elastic fiber homeostasis leads to pelvic floor disorders. Nat Genet. 2004;36(2):178-182.
19. Samsung Medical Center. LOXL1 polymorphism in pseudoexfoliation syndrome. Available from: http://clinicaltrials.gov/show/NCT01515735.NLM identifier: NCT01515735. Accessed July 1, 2013.
20. Tarkanen A, Reunanen A, Kvelä T. Frequency of systemic vascular diseases in patients with primary open angle glaucoma and exfoliation glaucoma. Acta Ophtamol. 2008;86(6):598-602.
21. Kim YM, Kim E, Kim Y. The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin. Mol Bio Rep. 2011;38(1):145-149.
22. Iftikhar M, Hurtado P, Bais MV, et al. Lysyl oxidase-like-2 (loxl2) is a major isoform in chondrocytes and is critically required for differentiation. J Biol Chem. 2011;286:909-918.
23. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like 2. J Hepatol. 2005;43(3):499-507.
24. Barry-Hamilton V, Spangler R, Marshall D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010;16(9):1009-1017.
25. Lee JE, Kim Y. A Tissue-specific variant of the human lysyl oxidaselike protein 3 (LOXL3) functions as an amine oxidase with substrate specificity. J Biol Chem. 2006;281(49):37282-37290.
26. Yu Q, Horak K, Larson DF. Role of T lymphocytes in hypertensioninduced cardiac extracellular matrix remodelling. Hypertension. 2006;48(1):98-104.
27. Ito H, Akiyama H, Iguchi H, et al. Molecular cloning and biological activity of a novel lysyl oxidase-related gene expressed in cartilage. J Biol Chem. 2001;276(26):24023-24029.
28. 1 through Smad and JunB/Fra2 and contributes to vascular matrix remodeling. Mol Cell Biol. 2013;33(12):2388-2401.
29. Ruiz La, Dutil J, Ruiz A, et al. Single-nucleotide polymorphisms in the lysyl oxidase-like protein 4 and complement component 3 genes are associated with increased risk for endometriosis and endometriosisassociated infertility. Fertil Steril. 2011;96(2):512-515.
30. Palamakumbura AH, Jeay S, Guo Y, et al. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 2004;279(39):40593-40600.
31. Kaneda A, Wakazono K, Tsukamoto T, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res. 2004;64(18):6410-6415.
32. Wu M, Min C, Wang X, et al. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res. 2007;67(13):6278-6285.
33. Cano A, Santamaría PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor progression. Future Oncol. 2012;8(9):1095-1108.
34. Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222-1226.
35. Pickup MW, Laklai H, Acerbi I, et al. Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-β-deficient mouse mammary carcinomas. Cancer Res. 2013;73(17):5336-5346.
36. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci U S A. 2008;105(17):6392-6397.
37. Baker AM, Cox TR, Bird D, et al. The role of lysyl oxidase in SRCdependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst. 2011;103(5):407-424.
38. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002;62(15):4478-4483.
39. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor progression by enhancing integrin signalling. Cell. 2009;139(5):891-906.
40. Schietke R, Warnecke C, Wacker I, et al. The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1. J Biol Chem. 2010;285(9):6658-6669.
41. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820-827.
42. Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35-44.
43. Wong CC, Gilkes DM, Zhang H, et al. Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A. 2011;108(39):16369-16374.
44. Decitre M, Gleyzal C, Raccurt M, et al. Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stroma reaction of ductal breast carcinomas. Lab Invest. 1998;78(2): 143-151.
45. Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. Lysyl oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol. 1997;150(2):497-507.
46. Pawson T, Linding R. Network Medicine. FEBS Lett. 2008;582(8): 1266-1270.
47. Lee MJ, Ye AS, Gardino AK, et al. Sequential et al. Cell. 2012;49(4): 780-794